Literature DB >> 10552096

Can the standardized uptake value characterize primary brain tumors on FDG-PET?

R Hustinx1, R J Smith, F Benard, A Bhatnagar, A Alavi.   

Abstract

The aim of this study was to evaluate the usefulness of measuring the standardized uptake value (SUV) in primary brain tumors on fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) scans. Two groups of patients were studied. Whole-brain glucose cerebral metabolic rates (wCMRs) and SUVs were obtained in 20 normal subjects. Twenty-seven patients with histology-proven malignant primary CNS tumors (high-grade gliomas n=22, primitive neuroectodermal tumors n=3, ependymomas n=2) were also studied. The degree of FDG uptake was assessed by visual inspection and thereafter regions of interest were placed over the lesion, the contralateral cortex and white matter and the whole brain. Average (avg) and maximum (max) pixel values were determined in each site. Based on these measurements, SUV, tumor to cortex (T/C) and tumor to white matter (T/WM) activity ratios were calculated. There was no correlation between wCMRs (4.55+/-0.36 mg min(-1) 100 g(-1)) and wSUVs (5.41+/-0.43) in the normal subjects (r=0.18, P=0.45). In the second group, 17 lesions were described as definitely and seven as probably malignant. However, SUVs in these tumors and in the contralateral cortex were not significantly different. Although the SUVs were generally higher in the tumor than in the contralateral white matter, there was a significant overlap between the values. The range of the SUVs was wide: 2.54-11.8 for the tumors, 2.98-9.96 for the cortex and 1.87-6.76 for the white matter. SUVs in the normal cortex were negatively correlated with blood glucose level at the time of the injection. SUVs in the whole brain and in the cortex were lower in patients previously treated by irradiation, even months after completion of the treatment. No correlation was detectable between any of the SUVs and the age of the patients, tumor type, time post injection, use of dexamethasone, patient weight, dose injected and visual score. With cutoff levels of 1.5 for T max/WM and 0.6 for T max/C, the sensitivity of the activity ratios was 74% and 96% respectively. In conclusion, SUVs do not correlate with CMRs across subjects and appear to be of limited value in characterizing brain tumors. Visual assessment and measurement of the activity ratios currently remain the most reliable methods of analysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10552096     DOI: 10.1007/s002590050487

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  22 in total

1.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

2.  [Preoperative imaging as the basis for image-guided neurosurgery].

Authors:  D Winkler; G Strauss; S Hesse; A Goldammer; M Hund-Georgiadis; A Richter; O Sabri; T Kahn; J Meixensberger
Journal:  Radiologe       Date:  2004-07       Impact factor: 0.635

3.  FDG-PET: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

4.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

5.  18F-FDG PET/CT in primary brain lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Mattia Bertoli; Raffaele Giubbini; Francesco Bertagna
Journal:  J Neurooncol       Date:  2017-11-17       Impact factor: 4.130

Review 6.  Brain tumors.

Authors:  Karl Herholz; Karl-Josef Langen; Christiaan Schiepers; James M Mountz
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

7.  Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat.

Authors:  Nicolas Spaeth; Matthias T Wyss; Jens Pahnke; Gregoire Biollaz; Amelie Lutz; Kerstin Goepfert; Gerrit Westera; Valerie Treyer; Bruno Weber; Alfred Buck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-15       Impact factor: 9.236

8.  Dual-time-point FDG-PET/CT for the detection of hepatic metastases.

Authors:  Albert Dirisamer; Benjamin S Halpern; Wolfgang Schima; Martin Heinisch; Florian Wolf; Mohsen Beheshti; Franz Dirisamer; Michael Weber; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2008-08-16       Impact factor: 3.488

9.  Reproducibility of semi-quantitative parameters in FDG-PET using two different PET scanners: influence of attenuation correction method and examination interval.

Authors:  Tomohito Kamibayashi; Tatsuro Tsuchida; Yoshiki Demura; Tetsuya Tsujikawa; Hidehiko Okazawa; Takashi Kudoh; Hirohiko Kimura
Journal:  Mol Imaging Biol       Date:  2008-04-12       Impact factor: 3.488

10.  Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.

Authors:  Deanna H Pafundi; Nadia N Laack; Ryan S Youland; Ian F Parney; Val J Lowe; Caterina Giannini; Brad J Kemp; Michael P Grams; Jonathan M Morris; Jason M Hoover; Leland S Hu; Jann N Sarkaria; Debra H Brinkmann
Journal:  Neuro Oncol       Date:  2013-03-03       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.